Immunoexpression of Bcl-2 in Breast Carcinoma: Association with Clinicopathological Parameters

Payman Anwar  Rashid; Noel S.  AL-Sakkal

doi:10.56056/amj.2015.08

Authors

Payman Anwar Rashid M.B.Ch.B, M.Sc Pathology FKBMS Lecturer Hawler Medical University College of Medicine Department of Pathology
Noel S. AL-Sakkal M.B.Ch.B, FRCPath (U.K) Assistant Professor in pathology

DOI:

https://doi.org/10.56056/amj.2015.08

Keywords:

Imunosupresio, Breast carcinoma

Abstract

Background and Objectives: Breast cancer is the most common malignancy in women. It is an
immensely heterogeneous disease, characterized by a broad variety of clinical development. The
research in recent years has focused on finding new markers of prognostic significance. Bcl-2, the
protein product of the Bcl-2 gene, is a member of the Bcl-2 family of proteins that play a crucial
role in a complex mechanism of apoptosis. It was recently proposed that Bcl-2 could inhibit cancer
progression. Aims of the study: To evaluate the role of Bcl-2 oncoprotein expression in patients
with breast carcinoma andits relation with various clinic pathological parameters.
Patients and Methods: Hundred cases of primary breast cancer were included in this prospective
retrospective study. The cases were collected from Rizgary Teaching Hospital and Private
Laboratories during a period of ten months from February to November 2013. The expression of
Bcl-2 oncoprotein was evaluated immunohis to chemically; the findings were correlated with the
age of the patients, size, type and grade of the tumor, lymph node status, vascular invasion, and the
estrogen and progesterone receptors.
Results: Bcl-2 oncoprotein was detected in 61 cases of primary breast cancer (61%). In this study
the majority of estrogen and progesterone receptors positive cases, (71%) and (59%) respectively,
showed positive Bcl-2 oncoprotein expression, (P=0.030) and (P=0.001) respectively. No
significant correlation with the age of the patient, size, type, grade of the tumor, lymph node status
nor with lymphovascular invasion could be found, (P=0.218), (P=0.410), (p=0.947), (p=0.938),
(p=0.190), (P=0.370) respectively.
Conclusions: Bcl-2 oncoprotein was frequently expressed in primary breast cancer. This study
revealed a significant correlation between Bcl-2 and the estrogen and progesterone receptors. Our
results suggest that Bcl-2 expression may be related to hormonal regulation. Larger patient study
groups with a long follow up period will be helpful to clarify the prognostic significance of Bcl-2

Downloads

Download data is not yet available.

References

American Cancer Society. Cancer Facts and Figures 2014. Atlanta: American Cancer Society; 2014: 5-9.

Crawford A. Bcl-2 Family Function in Antiestrogen-Resistant Breast Cancer Cells. A Dissertation for the degree of Doctor of Philosophy in Tumor Biology, Georgetown University, Washington; 2009: 22-24.

Callagy G.M, Pharoah P.D, Pinder S.E, et al. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin.Cancer Res 2006; 12: 2468-75.

Nadler Y, Camp RL, Giltnane JM, et al. Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Res 2008; 10(2): 35.

Callagy G.M, Webber M.J, Pharoah P.DP, et al. Me- ta-analysis confirms Bcl-2 is an independent prognostic marker in breast cancer. BMC Cancer 2008; 8: 153-54.

Oakes SR, Vaillant F, Lim E, et al. Sensitization of Bcl-2 expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. PNAS 2012; 109 (8).

Mohammed B and Ibrahim K. Bcl-2 oncoprotein expression in breast cancer, its relation to estrogen and progesterone receptors and other prognostic factors. Ann. Coll. Med. Mosul 2009; 35(2): 117-23.

Abdullhameed TT. The role of Bcl-2 and P53 immunoexpression in colorectal carcinoma. A thesis for the degree of Master of science in pathology, college of medicine, Hawler Medical University, Iraq; 2011: 36-38.

Lee HD, Koo JY and Jung WH. Correlation of Bcl-2 expression with clinicopathological features in Breast Cancer. Yonsei Medical Journal 1997; 38(4): 206-11.

Nathan B, Gusterson B and Jadayel D. Expression of Bcl-2 in primary breast cancer and its correlation with tumor phenotype. Ann Oncol 1994; 5 (5): 409-14.

Rosen P P. Rosen’s Breast Pathology. 3rd ed, Philadelphia Lippincott Williams & Wilkins, 2009: 264-69.

Emi M, Kim R, Tanabe K, et al. Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res 2005; 7: 940–52.

Thomadaki H, Talieri M and Scorilas A. Prognostic value of the apoptosis related genes Bcl-2 in breast cancer. Cancer Lett 2007; 247: 48–55.

Yang Q, Sakurai T, Yoshimura G, et al. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy. Oncol Rep 2003; 10:121–25.

Lee WY, Jin YT and Tzeng CC. Reciprocal expression of Bcl-2 and p53 in breast ductal carcinoma. Anti- cancer Res 1996;16: 3007–12.

Sierra A, Loveras B, Castellsague X, et al. Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int J Cancer1995; 60:54–60.

Hellemans P, van Dam PA, Weyler J, et al. Prognostic value of Bcl-2 expression in invasive breast cancer. Br J Cancer 1995; 72: 354–60.

Abd El-Mageed A.A, Mohamed A.S and ElesawyB.H. Different Prognostic Factors Correlate with Bcl- 2 Expression among Triple Negative and Non-Triple Negative Breast Cancers. Asian Pacific Journal of Can- cer Prevention. 2013; 14 (2): 1037-41.

Jalal FR. Detection of the C-myc gene status in cohort of archival human breast cancer patients using FISH, PCR, Tissue Microdissection and immunohistochemistry. A dissertation for the degree of Doctor of Philosophy in pathology, Faculty of Medical Science, Slemani University, Iraq; 2013: 35-39.

Wang Q , Kaaya E.E, Lihua C, et al. Expression of p53, Ki 67 and Bcl-2 Oncoprotein in Human Breast Cancer and Their Clinicopathological Significance. Austral-Asian Journal of Cancer 2004; 3 (4): 215-20.

Daidone M.G, Coradini D, Martelli G. et al. Primary breast cancer in elderly women: biological profile and relation with clinical outcome. Critical Review in Oncol./Hemat 2003; 45: 313-25.

Andalib A, Skokohi R, Rezaei A, et al. A Study of Tissue Bcl-2 Expression and =Its Serum Levels in Breast Cancer Patients. Gast. & Breast Ca. J 2007; 10: 2122.(Abstract).

Hun Lee K., Ah Im S., Youn Oh D. et al. Prognostic significance of Bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cy- clophophamide followed by paclitaxel as adjuvant che- motherapy. BMC Cancer 2007; 7: 63-70.

Cecka F, Hornychová H, Melichar B, et al. Expres- sion of Bcl-2 in breast cancer: correlation with clinico- pathological characteristics and survival. Acta Medica (Hradec Kralove) 2008; 51 (2): 107-12.

Dem A, Dragan S, Lazar E, et al. Bcl-2 Expression in Primary Breast Carcinoma: Correlation with Other Prognostic Factors. Journal of Experimental Medical & Surgical Research 2008;1(2): 65-71.

Bilalovic N, Vranic S, Hasanagic S, et al. The Bcl-2 protein: a prognostic indicator strongly related to ER and PR in breast cancer. Bosn J Basic Med Sci. 2004; 4 (4): 5-12.

Jaafar H, Abdullah S, Murtey M.D, et al. Expres- sion of Bax and Bcl-2 in Tumor Cells and Blood Vessels of Breast Cancer and their Association with Angiogenesis and Hormonal Receptors. Asian Pacific Journal of Cancer Prevention 2012; 13: 3857-62.

Park SH, Kim H and Song BJ. Down regulation of Bcl-2 expression in invasive ductal carcinomas is both estrogen and progesterone-receptor dependent and associated with poor prognostic factors. Pathol Oncol Res. 2002; 8: 26-30.

Dev K. Expression of antiapoptotic protein Bcl-2 and its correlation with histological grade and age in breast cancer. International Journal of Advanced Scientific and Technical Research 2013; 6(3): 553-63.

Munster PM and Norton L. Predictive factor for the response to adjuvant therapy with emphasis in breast cancer. Breast Cancer Res 2001; 3: 361-4.

Kharrat A F, Bouraoui S, Rahal K et al. P53 and Bcl-2 expression in breast cancer. Prospective study in Tunisia. Austral-Asian Journal of Cancer 2003; 2(2): 79-82.

Neri A, Marrelli D, Roviello F, et al. Bcl-2 expression correlates with lymphovascular invasion and long- term prognosis in breast cancer. Breast Cancer Res Treat 2006; 99: 77-83.

Linjawi A, Kontogiannea M, Halwani F, et al. Prog- nostic significance of p53, bcl-2, and Bax expression in early breast cancer. Journal of the American College of Surgeons 2004; 198 (1): 83-90.

Bayoudh I K, Hassen H B, Khabir A, et al. Bcl-2 expression and triple negative profile in breast carcinoma. Springer Science Business Media LLC 2010:173- 76.

Aggarwal H, Lubana P S, Jain DK, et al. Estima- tion of Bcl-2 protein in carcinoma of the breast and its clinical correlation in locally advanced breast cancer. J Cancer Res Ther 2007; 3 (4): 207-10.